Adjusted for cell proportions: FALSE IFX ADA IFX - ADA pooled enriched in B cells (I) (LI.M47.0) enriched in B cells (VI) (LI.M69) enriched in B cells (II) (LI.M47.1) -B cell surface signature (LI.S2) plasma cells & B cells, immunoglobulins (LI.M156.0) translation initiation factor 3 complex (LI.M245) enriched in B cells (III) (LI.M47.2) enriched in G-protein coupled receptors (LI.M130) enriched in NK cells (I) (LI.M7.2) -NK cell surface signature (LI.S1) antiviral IFN signature (LI.M75) -Effect size (AUC) recruitment of neutrophils (LI.M132) -0.5 cell adhesion (LI.M51) -0.6 platelet activation (II) (LI.M32.1) -Gene module cell cycle and growth arrest (LI.M31) platelet activation - actin binding (LI.M196) -TBA (LI.M198) -Direction of effect enriched in activated dendritic cells/monocytes (LI.M64) -Down in PR Not significant enriched in activated dendritic cells (II) (LI.M165) -Up in PR regulation of signal transduction (LI.M3) blood coagulation (LI.M11.1) -TBA (LI.M55) enriched in myeloid cells and monocytes (LI.M81) cell cycle and transcription (LI.M4.0) enriched in monocytes (IV) (LI.M118.0) -Monocyte surface signature (LI.S4) enriched in neutrophils (I) (LI.M37.1) -TLR and inflammatory signaling (LI.M16) enriched in monocytes (II) (LI.M11.0) immune activation - generic cluster (LI.M37.0) --log10(FDR)